Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Regn crawled time : 16:20 save search
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
libtayo cell treatment
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Published: 2023-03-18 (Crawled : 16:20) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
dupixent dermatitis show
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Published: 2023-03-18 (Crawled : 16:20) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
dupixent dermatitis show
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
cd20 phase 2
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Published: 2021-06-26 (Crawled : 16:20) - globenewswire.com
REGN | News | $899.71 0.32% 0.32% 340K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
NTLA | $21.85 1.3% 1.28% 1M
|
Health Technology
| Email alert
Add to watchlist
crispr disease therapy
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.